Engene Holdings Inc. (NASDAQ: ENGN) has announced the pricing of its public offering of common shares and pre-funded warrants. The offering consists of 12,558,823 common shares at a price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at a price of $8.4999 per pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $130 million.
Engene has granted the underwriters a 30-day option to purchase up to 2,294,117 additional common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 14, 2025.
The securities are being offered by Engene pursuant to its effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on November 13, 2024, and declared effective on November 21, 2024.
Engene is a clinical-stage biotechnology company focused on delivering therapeutics to mucosal tissues and other organs to address diseases with high clinical needs. Its lead program, detalimogene voraplasmid, is being evaluated in the ongoing multi-cohort Legend Phase 2 trial for patients with non-muscle invasive bladder cancer. This program was developed using Engene’s proprietary dually derivatized oligochitosan platform.
The joint book running managers for the offering are Jefferies, Leerink Partners, and Wells Fargo Securities, while Raymond James and Van Lanschot Kempen are acting as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager for the offering. Following these announcements, the company's shares moved 3.2%, and are now trading at a price of $8.70. For more information, read the company's full 8-K submission here.
